The research focused on the pharmaceutical treatment of Ebola infection has produced somewhat disappointing results. One candidate drug, TKM-Ebola, after showing promise in primates, has subsequently been demonstrated to be ineffective in treating human Ebola infection.[54] Although the other experimental IgG-based monoclonal antibody-based drug ZMapp has shown good efficacy in primates,[55] there is no compelling evidence that it is effective in humans.[56] In addition, despite a poorly defined safety profile, the drug recently received fast track approval by the Food and Drug Administration (FDA).[57]